Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xgeva

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

- PMLiVE

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

First new drug for the disease in the EU since 2010

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

- PMLiVE

Nucala works in rare inflammatory disease, says GSK

Company is planning to file for approval in indication next year

- PMLiVE

The long and winding road to asthma breakthroughs

Respiratory biologics are booming thanks to scientists who refused to be derailed by early research setbacks

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Amgen exits neuroscience R&D to focus on growth areas

Move has resulted in loss of around 180 jobs

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links